Dean et al., 2018 - Google Patents
The use of NLR, PLR and CA19. 9 as prognostic markers for locally advanced pancreatic cancerDean et al., 2018
View PDF- Document ID
- 5959202699632875841
- Author
- Dean A
- Higgs D
- Das A
- Fennessy S
- Rogers-Seeley M
- McGarvey C
- McNulty M
- Publication year
- Publication venue
- Annals of Oncology
External Links
Snippet
Methods: A retrospective cohort study was conducted for 66 patients with locally advanced pancreatic cancer who received chemotherapy only (C), chemotherapy plus radiotherapy (CRT) or chemotherapy plus radiotherapy then surgery (CRTS) between January 2014 and …
- 208000008443 Pancreatic Carcinoma 0 title abstract description 19
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11229689B2 (en) | Methods of cancer treatment using activated T cells | |
Papadatos-Pastos et al. | Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors | |
He et al. | Biomarkers and future perspectives for hepatocellular carcinoma immunotherapy | |
Chung et al. | A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer | |
Yang et al. | Immunotherapy with immune checkpoint inhibitors for advanced colorectal cancer: a promising individualized treatment strategy | |
Dean et al. | The use of NLR, PLR and CA19. 9 as prognostic markers for locally advanced pancreatic cancer | |
EP3313431B1 (en) | Method for inducing early t memory response with short peptides anti-tumor vaccine | |
Sun et al. | Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer | |
Ascierto et al. | Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy) | |
BR112021014657A2 (en) | METHODS TO TREAT PROSTATE CANCER BASED ON MOLECULAR SUBTYPES | |
Li et al. | 34th annual meeting & pre-conference programs of the society for immunotherapy of cancer (SITC 2019): part 2 | |
Yusuf et al. | Antibodies matter: A meta-analysis of the prognostic value of human equilibrative nucleoside transporter 1 (hENT1) antibodies in pancreatobiliary cancer | |
Paliogiannis et al. | Blood cell count indexes of systemic inflammation as predictive biomarkers of immunotherapy outcomes in advanced non-small-cell lung cancer | |
Hack et al. | Augmenting anticancer immunity through combined targeting of angiogenic and PD-1 | |
Sundar et al. | Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes | |
Shatara et al. | ATRT-21. Rhabdoid predisposition syndrome: report of molecular profiles and treatment approach in three children with synchronous atypical teratoid/rhabdoid tumor and malignant rhabdoid tumor | |
Park et al. | 8/# 234 Immune properties of tumor-infiltrating lymphocytes in ovarian clear cell carcinoma relative to ovarian high-grade serous carcinoma | |
Finetti et al. | ATRT-25. INTEGRATED QUANTITATIVE SWATH-MS PROTEOMICS ANALYSIS OF ATRTs UNCOVERS NEW THERAPEUTIC OPPORTUNITIES | |
Cui et al. | Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy | |
Jang et al. | Comparing efficacy of 1-L Peg-Asc with prucalopride versus 2-L Peg-Asc for bowel preparation | |
CN111316101B (en) | Predicting responders to cyclophosphamide therapy | |
Mao et al. | Weijie Ma1, 2†, Sixi Wei1†, Siqi Long1, Eddie C. Tian1, Bridget McLaughlin3, Maria Jaimes 4, Dennis J. Montoya5, Varun R. Viswanath1, Jeremy Chien5, Qianjun Zhang6, Jonathan E. Van Dyke3, Shuai Chen 7 and Tianhong Li1, 8 | |
Jeon et al. | Endoscopic detachable auxiliary manipulator in endoscopic submucosal dissection: Animal model studY | |
Wang | The Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitor in≥ 3 line MSS Metastatic Colorectal Cancer Patients | |
NAG et al. | Species Contribution Reference Number |